<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39027374</PMID><DateRevised><Year>2024</Year><Month>07</Month><Day>20</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2589-0042</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>iScience</Title><ISOAbbreviation>iScience</ISOAbbreviation></Journal><ArticleTitle>sMR and PTX3 levels associate with COVID-19 outcome and survival but not with Long COVID.</ArticleTitle><Pagination><StartPage>110162</StartPage><MedlinePgn>110162</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">110162</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.isci.2024.110162</ELocationID><Abstract><AbstractText>Biomarkers for monitoring COVID-19 disease course are lacking. Study aim was to identify biomarkers associated with disease severity, survival, long-term outcome, and Long COVID. As excessive macrophages activation is a hallmark of COVID-19 and complement activation is key in this, we selected the following proteins involved in these processes: PTX3, C1q, C1-INH, C1s/C1-INH, and sMR. EDTA-plasma concentrations were measured in 215 patients and 47 controls using ELISA. PTX3, sMR, C1-INH, and C1s/C1-INH levels were associated with disease severity. PTX3 and sMR were also associated with survival and long-term immune recovery. Lastly, sMR levels associate with ICU admittance. sMR (AUC 0.85) and PTX3 (AUC 0.78) are good markers for disease severity, especially when used in combination (AUC 0.88). No association between biomarker levels and Long COVID was observed. sMR has not previously been associated with COVID-19 disease severity, ICU admittance or survival and may serve as marker for disease course.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurler</LastName><ForeName>Lisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mescia</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bergamaschi</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration</CollectiveName></Author><Author ValidYN="Y"><LastName>Kajd&#xe1;csi</LastName><ForeName>Erika</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sinkovits</LastName><ForeName>Gy&#xf6;rgy</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cervenak</LastName><ForeName>L&#xe1;szl&#xf3;</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Proh&#xe1;szka</LastName><ForeName>Zolt&#xe1;n</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Group for Immunology and Haematology, Semmelweis University - E&#xf6;tv&#xf6;s Lor&#xe1;nd Research Network (Office for Supported Research Groups), Budapest, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>Paul A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Cambridge Institute of Therapeutic Immunology and Infectious Disease, Jeffrey Cheah Biomedical Centre, University of Cambridge, Cambridge CB2 0AW, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toonen</LastName><ForeName>Erik J M</ForeName><Initials>EJM</Initials><AffiliationInfo><Affiliation>Research and Development Department, Hycult Biotech, Uden, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>iScience</MedlineTA><NlmUniqueID>101724038</NlmUniqueID><ISSNLinking>2589-0042</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Molecular biology</Keyword><Keyword MajorTopicYN="N">Virology</Keyword></KeywordList><CoiStatement>E.T. is an employee of Hycult Biotechnology b.v.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>12</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>7</Month><Day>19</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39027374</ArticleId><ArticleId IdType="pmc">PMC11255846</ArticleId><ArticleId IdType="doi">10.1016/j.isci.2024.110162</ArticleId><ArticleId IdType="pii">S2589-0042(24)01387-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Organization W.H. COVID-19&#xa0;weekly epidemiological update. 2023. https://www.who.int/emergencies/diseases/novel-coronavirus-2019</Citation></Reference><Reference><Citation>Renu K., Prasanna P.L., Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage - A review. Life Sci. 2020;255 doi: 10.1016/j.lfs.2020.117839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117839</ArticleId><ArticleId IdType="pmc">PMC7243768</ArticleId><ArticleId IdType="pubmed">32450165</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachelle H., Malak G., Houry P., Marc H., Sacha S., Yara G., Joseph E.B., Anthony Y., Ghinwa H., Celine M., et al. Mortality risk in patients with obesity and COVID-19 infection: a systematic review and meta-analysis. Metabolism. 2024;155 doi: 10.1016/j.metabol.2024.155812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.metabol.2024.155812</ArticleId><ArticleId IdType="pubmed">38360130</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M., Piernas C., Astbury N.M., Hippisley-Cox J., O'Rahilly S., Aveyard P., Jebb S.A. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 2021;9:350&#x2013;359. doi: 10.1016/S2213-8587(21)00089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00089-9</ArticleId><ArticleId IdType="pmc">PMC8081400</ArticleId><ArticleId IdType="pubmed">33932335</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. J.&#xa0;Clin. Invest. 2022;132 doi: 10.1172/JCI161167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A., Vlok M., Turner S., Venter C., Laubscher G.J., Kell D.B., Pretorius E. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc. Diabetol. 2022;21:190. doi: 10.1186/s12933-022-01623-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01623-4</ArticleId><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>V'Kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155&#x2013;170. doi: 10.1038/s41579-020-00468-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00468-6</ArticleId><ArticleId IdType="pmc">PMC7592455</ArticleId><ArticleId IdType="pubmed">33116300</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim E.H.T., van Amstel R.B.E., de Boer V.V., van Vught L.A., de Bruin S., Brouwer M.C., Vlaar A.P.J., van de Beek D. Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Rev. 2023;57 doi: 10.1016/j.blre.2022.100995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.100995</ArticleId><ArticleId IdType="pmc">PMC9338830</ArticleId><ArticleId IdType="pubmed">35934552</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nooijer A.H., Grondman I., Janssen N.A.F., Netea M.G., Willems L., van de Veerdonk F.L., Giamarellos-Bourboulis E.J., Toonen E.J.M., Joosten L.A.B., RCI-COVID-19 study group Complement Activation in the Disease Course of Coronavirus Disease 2019 and Its Effects on Clinical Outcomes. J.&#xa0;Infect. Dis. 2021;223:214&#x2013;224. doi: 10.1093/infdis/jiaa646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa646</ArticleId><ArticleId IdType="pmc">PMC7797765</ArticleId><ArticleId IdType="pubmed">33038254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergamaschi L., Mescia F., Turner L., Hanson A.L., Kotagiri P., Dunmore B.J., Ruffieux H., De Sa A., Huhn O., Morgan M.D., et al. Longitudinal analysis reveals that delayed bystander CD8+ T&#xa0;cell activation and early immune pathology distinguish severe COVID-19 from mild disease. Immunity. 2021;54:1257&#x2013;1275.e8. doi: 10.1016/j.immuni.2021.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.05.010</ArticleId><ArticleId IdType="pmc">PMC8125900</ArticleId><ArticleId IdType="pubmed">34051148</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajishengallis G., Reis E.S., Mastellos D.C., Ricklin D., Lambris J.D. Novel mechanisms and functions of complement. Nat. Immunol. 2017;18:1288&#x2013;1298. doi: 10.1038/ni.3858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3858</ArticleId><ArticleId IdType="pmc">PMC5706779</ArticleId><ArticleId IdType="pubmed">29144501</ArticleId></ArticleIdList></Reference><Reference><Citation>Schanzenbacher J., K&#xf6;hl J., Karsten C.M. Anaphylatoxins spark the flame in early autoimmunity. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.958392.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.958392</ArticleId><ArticleId IdType="pmc">PMC9358992</ArticleId><ArticleId IdType="pubmed">35958588</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderbeke L., Van Mol P., Van Herck Y., De Smet F., Humblet-Baron S., Martinod K., Antoranz A., Arijs I., Boeckx B., Bosisio F.M., et al. Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity. Nat. Commun. 2021;12:4117. doi: 10.1038/s41467-021-24360-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24360-w</ArticleId><ArticleId IdType="pmc">PMC8257697</ArticleId><ArticleId IdType="pubmed">34226537</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H., Lao Q., Zhang J., Zhu J. Coagulopathy in COVID-19 and anticoagulation clinical trials. Best Pract. Res. Clin. Haematol. 2022;35 doi: 10.1016/j.beha.2022.101377.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2022.101377</ArticleId><ArticleId IdType="pmc">PMC9395291</ArticleId><ArticleId IdType="pubmed">36494146</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubieta-Calleja G.R., Zubieta-DeUrioste N., de Jes&#xfa;s Montelongo F., Sanchez M.G.R., Campoverdi A.F., Rocco P.R.M., Battaglini D., Ball L., Pelosi P. Morphological and functional findings in COVID-19 lung disease as compared to Pneumonia, ARDS, and High-Altitude Pulmonary Edema. Respir. Physiol. Neurobiol. 2023;309 doi: 10.1016/j.resp.2022.104000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resp.2022.104000</ArticleId><ArticleId IdType="pmc">PMC9707029</ArticleId><ArticleId IdType="pubmed">36460252</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson B., Persson B., Eriksson O., Fromell K., Hultstr&#xf6;m M., Frithiof R., Lipcsey M., Huber-Lang M., Ekdahl K.N. How the Innate Immune System of the Blood Contributes to Systemic Pathology in COVID-19-Induced ARDS and Provides Potential Targets for Treatment. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.840137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.840137</ArticleId><ArticleId IdType="pmc">PMC8957861</ArticleId><ArticleId IdType="pubmed">35350780</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydin Y., Vemuri B., Vajta Gomez J.P., Challa P.K., Zhang H. Fatal Gets More Fatal: A COVID-19 Infection With Macrophage Activation Syndrome. Cureus. 2022;14 doi: 10.7759/cureus.25591.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.25591</ArticleId><ArticleId IdType="pmc">PMC9250044</ArticleId><ArticleId IdType="pubmed">35795500</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G., Deutsch G.H., Schulert G.S., Zheng H., Jang S., Trapnell B., Lee P.Y., Macaubas C., Ho K., Schneider C., et al. Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis Rheumatol. 2022;74:1271&#x2013;1283. doi: 10.1002/art.42099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42099</ArticleId><ArticleId IdType="pmc">PMC9246966</ArticleId><ArticleId IdType="pubmed">35189047</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh D., Lim J.C.T., Ferna&#xed;ndez S.B., Joseph C.R., Edwards S.G., Neo Z.W., Lee J.N., Caballero S.G., Lau M.C., Yeong J.P.S. Case report: Persistence of residual antigen and RNA of the SARS-CoV-2 virus in tissues of two patients with long COVID. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.939989.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.939989</ArticleId><ArticleId IdType="pmc">PMC9483160</ArticleId><ArticleId IdType="pubmed">36131932</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovits G., Schnur J., Hurler L., Kiszel P., Proh&#xe1;szka Z.Z., S&#xed;k P., Kajd&#xe1;csi E., Cervenak L., Mar&#xe1;czi V., D&#xe1;vid M., et al. Evidence, detailed characterization and clinical context of complement activation in acute multisystem inflammatory syndrome in children. Sci. Rep. 2022;12 doi: 10.1038/s41598-022-23806-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-23806-5</ArticleId><ArticleId IdType="pmc">PMC9670087</ArticleId><ArticleId IdType="pubmed">36396679</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavillegrand J.R., Garnier M., Spaeth A., Mario N., Hariri G., Pilon A., Berti E., Fieux F., Thietart S., Urbina T., et al. Correction to: Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: infammatory response of SARS-CoV-2 patients. Ann. Intensive Care. 2021;11:93. doi: 10.1186/s13613-021-00879-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-021-00879-5</ArticleId><ArticleId IdType="pmc">PMC8188151</ArticleId><ArticleId IdType="pubmed">34106340</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil S., Gondhali G., Acharya A. "Serial ferritin titer" monitoring in COVID-19 pneumonia: valuable inflammatory marker in assessment of severity and predicting early lung fibrosis - prospective, multicentric, observational, and interventional study in tertiary care setting in India. Egypt. J. Intern. Med. 2022;34:75. doi: 10.1186/s43162-022-00163-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43162-022-00163-3</ArticleId><ArticleId IdType="pmc">PMC9556145</ArticleId><ArticleId IdType="pubmed">36254195</ArticleId></ArticleIdList></Reference><Reference><Citation>Baillie K., Davies H.E., Keat S.B.K., Ladell K., Miners K.L., Jones S.A., Mellou E., Toonen E.J.M., Price D.A., Morgan B.P., et al. Complement dysregulation is a prevalent and therapeutically amenable feature of long COVID. Med. 2024;5:239&#x2013;253.e5. doi: 10.1016/j.medj.2024.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medj.2024.01.011</ArticleId><ArticleId IdType="pubmed">38359836</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti V., Corbi G., Sabbatino F., De Pascale D., Sellitto C., Stefanelli B., Bertini N., De Simone M., Liguori L., Di Paola I., et al. Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches. J.&#xa0;Pers. Med. 2023;13 doi: 10.3390/jpm13020334.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jpm13020334</ArticleId><ArticleId IdType="pmc">PMC9959656</ArticleId><ArticleId IdType="pubmed">36836568</ArticleId></ArticleIdList></Reference><Reference><Citation>Embgenbroich M., van der Zande H.J.P., Hussaarts L., Schulte-Schrepping J., Pelgrom L.R., Garc&#xed;a-Tard&#xf3;n N., Schlautmann L., Stoetzel I., H&#xe4;ndler K., Lambooij J.M., et al. Soluble mannose receptor induces proinflammatory macrophage activation and metaflammation. Proc. Natl. Acad. Sci. USA. 2021;118 doi: 10.1073/pnas.2103304118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2103304118</ArticleId><ArticleId IdType="pmc">PMC8346872</ArticleId><ArticleId IdType="pubmed">34326259</ArticleId></ArticleIdList></Reference><Reference><Citation>Haapasalo K., Meri S. Regulation of the Complement System by Pentraxins. Front. Immunol. 2019;10:1750. doi: 10.3389/fimmu.2019.01750.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01750</ArticleId><ArticleId IdType="pmc">PMC6688104</ArticleId><ArticleId IdType="pubmed">31428091</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunetta E., Folci M., Bottazzi B., De Santis M., Gritti G., Protti A., Mapelli S.N., Bonovas S., Piovani D., Leone R., et al. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 2021;22:19&#x2013;24. doi: 10.1038/s41590-020-00832-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00832-x</ArticleId><ArticleId IdType="pubmed">33208929</ArticleId></ArticleIdList></Reference><Reference><Citation>Protti A., Meessen J., Bottazzi B., Garlanda C., Milani A., Bacci M., Mantovani A., Cecconi M., Latini R., Caironi P. Circulating pentraxin 3 in severe COVID-19 or other pulmonary sepsis. Eur. J. Clin. Invest. 2021;51 doi: 10.1111/eci.13530.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13530</ArticleId><ArticleId IdType="pmc">PMC7995110</ArticleId><ArticleId IdType="pubmed">33660256</ArticleId></ArticleIdList></Reference><Reference><Citation>Lage S.L., Rocco J.M., Laidlaw E., Rupert A., Galindo F., Kellogg A., Kumar P., Poon R., Wortmann G.W., Lisco A., et al. Activation of Complement Components on Circulating Blood Monocytes From COVID-19 Patients. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.815833.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.815833</ArticleId><ArticleId IdType="pmc">PMC8892247</ArticleId><ArticleId IdType="pubmed">35250994</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurler L., Toonen E.J.M., Kajd&#xe1;csi E., van Bree B., Brandwijk R.J.M.G.E., de Bruin W., Lyons P.A., Bergamaschi L., Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research CITIID-NIHR COVID BioResource Collaboration. Sinkovits G., et al. Distinction of early complement classical and lectin pathway activation via quantification of C1s/C1-INH and MASP-1/C1-INH complexes using novel ELISAs. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.1039765.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.1039765</ArticleId><ArticleId IdType="pmc">PMC9677118</ArticleId><ArticleId IdType="pubmed">36420270</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen B., Yi X., Sun Y., Bi X., Du J., Zhang C., Quan S., Zhang F., Sun R., Qian L., et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. Cell. 2020;182:59&#x2013;72.e15. doi: 10.1016/j.cell.2020.05.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.032</ArticleId><ArticleId IdType="pmc">PMC7254001</ArticleId><ArticleId IdType="pubmed">32492406</ArticleId></ArticleIdList></Reference><Reference><Citation>Charitos P., Heijnen I.A.F.M., Egli A., Bassetti S., Trendelenburg M., Osthoff M. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.765330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.765330</ArticleId><ArticleId IdType="pmc">PMC8581394</ArticleId><ArticleId IdType="pubmed">34777382</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilling D., Galvis-Carvajal E., Karhadkar T.R., Cox N., Gomer R.H. Monocyte differentiation and macrophage priming are regulated differentially by pentraxins and their ligands. BMC Immunol. 2017;18:30. doi: 10.1186/s12865-017-0214-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-017-0214-z</ArticleId><ArticleId IdType="pmc">PMC5472910</ArticleId><ArticleId IdType="pubmed">28619036</ArticleId></ArticleIdList></Reference><Reference><Citation>Loonen A.J.M., Leijtens S., Serin O., Hilbink M., Wever P.C., van den Brule A.J.C., Toonen E.J.M. Soluble mannose receptor levels in blood correlate to disease severity in patients with community-acquired pneumonia. Immunol. Lett. 2019;206:28&#x2013;32. doi: 10.1016/j.imlet.2018.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2018.12.001</ArticleId><ArticleId IdType="pubmed">30521839</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchiya K., Suzuki Y., Yoshimura K., Yasui H., Karayama M., Hozumi H., Furuhashi K., Enomoto N., Fujisawa T., Nakamura Y., et al. Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia. Sci. Rep. 2019;9 doi: 10.1038/s41598-019-55289-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-55289-2</ArticleId><ArticleId IdType="pmc">PMC6904766</ArticleId><ArticleId IdType="pubmed">31822747</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgaard-Hansen S., Rafique A., Christensen P.A., Maniecki M.B., Sandahl T.D., Nexo E., Moller H.J. A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness. Clin. Chem. Lab. Med. 2014;52:453&#x2013;461. doi: 10.1515/cclm-2013-0451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2013-0451</ArticleId><ArticleId IdType="pubmed">24114918</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodgaard-Hansen S., Rafique A., Weis N., Wejse C., Nielsen H., Pedersen S.S., Moller H.J., Kronborg G. Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival. Infect. Dis. 2015;47:203&#x2013;208. doi: 10.3109/00365548.2014.984321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00365548.2014.984321</ArticleId><ArticleId IdType="pubmed">25650730</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurler L., Szil&#xe1;gyi &#xc1;., Mescia F., Bergamaschi L., Mez&#x151; B., Sinkovits G., R&#xe9;ti M., M&#xfc;ller V., Iv&#xe1;nyi Z., G&#xe1;l J., et al. Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1162171.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1162171</ArticleId><ArticleId IdType="pmc">PMC10084477</ArticleId><ArticleId IdType="pubmed">37051252</ArticleId></ArticleIdList></Reference><Reference><Citation>Katzenschlager S., Zimmer A.J., Gottschalk C., Grafeneder J., Schmitz S., Kraker S., Ganslmeier M., Muth A., Seitel A., Maier-Hein L., et al. Can we predict the severe course of COVID-19 - a systematic review and meta-analysis of indicators of clinical outcome? PLoS One. 2021;16 doi: 10.1371/journal.pone.0255154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0255154</ArticleId><ArticleId IdType="pmc">PMC8321230</ArticleId><ArticleId IdType="pubmed">34324560</ArticleId></ArticleIdList></Reference><Reference><Citation>Espin E., Yang C., Shannon C.P., Assadian S., He D., Tebbutt S.J. Cellular and molecular biomarkers of long COVID: a scoping review. EBioMedicine. 2023;91 doi: 10.1016/j.ebiom.2023.104552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2023.104552</ArticleId><ArticleId IdType="pmc">PMC10082390</ArticleId><ArticleId IdType="pubmed">37037165</ArticleId></ArticleIdList></Reference><Reference><Citation>Assandri R., Accordino S., Canetta C., Buscarini E., Scartabellati A., Tolassi C., Serana F. Long pentraxin 3 as a marker of COVID-19 severity: evidences and perspectives. Biochem. Med. 2022;32 doi: 10.11613/BM.2022.020901.</Citation><ArticleIdList><ArticleId IdType="doi">10.11613/BM.2022.020901</ArticleId><ArticleId IdType="pmc">PMC8996318</ArticleId><ArticleId IdType="pubmed">35464745</ArticleId></ArticleIdList></Reference><Reference><Citation>Tong M., Xiong Y., Zhu C., Xu H., Zheng Q., Hu C., Jiang Y., Zou L., Xiao X., Chen F., et al. Elevated Serum Pentraxin-3 Levels is Positively Correlated to Disease Severity and Coagulopathy in COVID-19 Patients. Mediterr. J. Hematol. Infect. Dis. 2021;13 doi: 10.4084/MJHID.2021.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.4084/MJHID.2021.015</ArticleId><ArticleId IdType="pmc">PMC7813280</ArticleId><ArticleId IdType="pubmed">33489054</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.B., Sandholdt H., M&#xf8;ller M.E.E., P&#xe9;rez-Al&#xf3;s L., Pedersen L., Bastrup Israelsen S., Garred P., Benfield T. Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3. J.&#xa0;Innate Immun. 2022;14:493&#x2013;501. doi: 10.1159/000521612.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000521612</ArticleId><ArticleId IdType="pmc">PMC9059012</ArticleId><ArticleId IdType="pubmed">35066500</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapadula G., Leone R., Bernasconi D.P., Biondi A., Rossi E., D'Angi&#xf2; M., Bottazzi B., Bettini L.R., Beretta I., Garlanda C., et al. Long pentraxin 3 (PTX3) levels predict death, intubation and thrombotic events among hospitalized patients with COVID-19. Front. Immunol. 2022;13 doi: 10.3389/fimmu.2022.933960.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.933960</ArticleId><ArticleId IdType="pmc">PMC9651085</ArticleId><ArticleId IdType="pubmed">36389697</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutmann C., Takov K., Burnap S.A., Singh B., Ali H., Theofilatos K., Reed E., Hasman M., Nabeebaccus A., Fish M., et al. SARS-CoV-2 RNAemia and proteomic trajectories inform prognostication in COVID-19 patients admitted to intensive care. Nat. Commun. 2021;12:3406. doi: 10.1038/s41467-021-23494-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-23494-1</ArticleId><ArticleId IdType="pmc">PMC8184784</ArticleId><ArticleId IdType="pubmed">34099652</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo C., Li Z. Bioinformatics Analysis of Key Genes and Pathways Associated with Thrombosis in Essential Thrombocythemia. Med. Sci. Monit. 2019;25:9262&#x2013;9271. doi: 10.12659/MSM.918719.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.918719</ArticleId><ArticleId IdType="pmc">PMC6911306</ArticleId><ArticleId IdType="pubmed">31801935</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojnar E., J&#xf3;zsi M., Szab&#xf3; Z., R&#xe9;ti M., Farkas P., Kelen K., Reusz G.S., Szab&#xf3; A.J., Garam N., Mikes B., et al. Elevated Systemic Pentraxin-3 Is Associated With Complement Consumption in the Acute Phase of Thrombotic Microangiopathies. Front. Immunol. 2019;10:240. doi: 10.3389/fimmu.2019.00240.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00240</ArticleId><ArticleId IdType="pmc">PMC6397851</ArticleId><ArticleId IdType="pubmed">30858847</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan L.Y., Komarasamy T.V., Rmt Balasubramaniam V. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.742941.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.742941</ArticleId><ArticleId IdType="pmc">PMC8515020</ArticleId><ArticleId IdType="pubmed">34659238</ArticleId></ArticleIdList></Reference><Reference><Citation>Noone D.P., Dijkstra D.J., van der Klugt T.T., van Veelen P.A., de Ru A.H., Hensbergen P.J., Trouw L.A., Sharp T.H. PTX3 structure determination using a hybrid cryoelectron microscopy and AlphaFold approach offers insights into ligand binding and complement activation. Proc. Natl. Acad. Sci. USA. 2022;119 doi: 10.1073/pnas.2208144119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2208144119</ArticleId><ArticleId IdType="pmc">PMC9388099</ArticleId><ArticleId IdType="pubmed">35939690</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinkovits G., Mez&#x151; B., R&#xe9;ti M., M&#xfc;ller V., Iv&#xe1;nyi Z., G&#xe1;l J., Gopcsa L., Rem&#xe9;nyi P., Szathm&#xe1;ry B., Lakatos B., et al. Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.663187.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.663187</ArticleId><ArticleId IdType="pmc">PMC8027327</ArticleId><ArticleId IdType="pubmed">33841446</ArticleId></ArticleIdList></Reference><Reference><Citation>Pires B.G., Calado R.T. Hyper-inflammation and complement in COVID-19. Am. J. Hematol. 2023;98:S74&#x2013;S81. doi: 10.1002/ajh.26746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.26746</ArticleId><ArticleId IdType="pubmed">36999459</ArticleId></ArticleIdList></Reference><Reference><Citation>Meroni P.L., Croci S., Lonati P.A., Pregnolato F., Spaggiari L., Besutti G., Bonacini M., Ferrigno I., Rossi A., Hetland G., et al. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients. Autoimmun. Rev. 2023;22 doi: 10.1016/j.autrev.2022.103232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2022.103232</ArticleId><ArticleId IdType="pmc">PMC9675082</ArticleId><ArticleId IdType="pubmed">36414219</ArticleId></ArticleIdList></Reference><Reference><Citation>Doni A., Garlanda C., Bottazzi B., Meri S., Garred P., Mantovani A. Interactions of the humoral pattern recognition molecule PTX3 with the complement system. Immunobiology. 2012;217:1122&#x2013;1128. doi: 10.1016/j.imbio.2012.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2012.07.004</ArticleId><ArticleId IdType="pubmed">22964239</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyskida K., Franik G., Pohl N., Markuszewski L., Owczarek A., Madej P., Chudek J., Olszanecka-Glinianowicz M. Pentraxin 3 as a marker of endothelial dysfunction in young women with polycystic ovary syndrome (PCOS) Scand. J. Clin. Lab. Invest. 2019;79:419&#x2013;423. doi: 10.1080/00365513.2019.1637535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00365513.2019.1637535</ArticleId><ArticleId IdType="pubmed">31282210</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg H., J&#xe9;gouzo S.A.F., Lasanajak Y., Smith D.F., Drickamer K., Weis W.I., Taylor M.E. Structural analysis of carbohydrate binding by the macrophage mannose receptor CD206. J.&#xa0;Biol. Chem. 2021;296 doi: 10.1016/j.jbc.2021.100368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2021.100368</ArticleId><ArticleId IdType="pmc">PMC7949135</ArticleId><ArticleId IdType="pubmed">33545173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazi U., Rosas M., Singh S., Heinsbroek S., Haq I., Johnson S., Brown G.D., Williams D.L., Taylor P.R., Martinez-Pomares L. Fungal recognition enhances mannose receptor shedding through dectin-1 engagement. J.&#xa0;Biol. Chem. 2011;286:7822&#x2013;7829. doi: 10.1074/jbc.M110.185025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.185025</ArticleId><ArticleId IdType="pmc">PMC3048669</ArticleId><ArticleId IdType="pubmed">21205820</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen M.C., Andersen M.N., Rittig N., R&#xf8;dgaard-Hansen S., Gr&#xf8;nbaek H., Moestrup S.K., M&#xf8;ller H.J., Etzerodt A. The macrophage-related biomarkers sCD163 and sCD206 are released by different shedding mechanisms. J.&#xa0;Leukoc. Biol. 2019;106:1129&#x2013;1138. doi: 10.1002/JLB.3A1218-500R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/JLB.3A1218-500R</ArticleId><ArticleId IdType="pubmed">31242338</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel S., Quickert S., Lutz P., Ibidapo-Obe O., Steube A., K&#xf6;se-Vogel N., Yarbakht M., Reuken P.A., Busch M., Brandt A., et al. Peritoneal Level of CD206 Associates With Mortality and an Inflammatory Macrophage Phenotype in Patients With Decompensated Cirrhosis and Spontaneous Bacterial Peritonitis. Gastroenterology. 2020;158:1745&#x2013;1761. doi: 10.1053/j.gastro.2020.01.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.01.029</ArticleId><ArticleId IdType="pubmed">31982413</ArticleId></ArticleIdList></Reference><Reference><Citation>Fraser I.P., Takahashi K., Koziel H., Fardin B., Harmsen A., Ezekowitz R.A. Pneumocystis carinii enhances soluble mannose receptor production by macrophages. Microbes Infect. 2000;2:1305&#x2013;1310. doi: 10.1016/s1286-4579(00)01283-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s1286-4579(00)01283-1</ArticleId><ArticleId IdType="pubmed">11018446</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Zande H.J.P., Nitsche D., Schlautmann L., Guigas B., Burgdorf S. The Mannose Receptor: From Endocytic Receptor and Biomarker to Regulator of (Meta)Inflammation. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.765034.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.765034</ArticleId><ArticleId IdType="pmc">PMC8551360</ArticleId><ArticleId IdType="pubmed">34721436</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen M.C., Hvidbjerg Gantzel R., Claria J., Trebicka J., Moller H.J., Gronbaek H. Macrophage activation markers, CD163 and CD206, in acute-on-chronic liver failure. Cells. 2020;9 doi: 10.3390/cells9051175.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9051175</ArticleId><ArticleId IdType="pmc">PMC7290463</ArticleId><ArticleId IdType="pubmed">32397365</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki Y., Shirai M., Asada K., Yasui H., Karayama M., Hozumi H., Furuhashi K., Enomoto N., Fujisawa T., Nakamura Y., et al. Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis. Sci. Rep. 2018;8 doi: 10.1038/s41598-018-31565-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31565-5</ArticleId><ArticleId IdType="pmc">PMC6120933</ArticleId><ArticleId IdType="pubmed">30177769</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen M.N., Andersen N.F., R&#xf8;dgaard-Hansen S., Hokland M., Abildgaard N., M&#xf8;ller H.J. The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma. Leuk. Res. 2015;39:971&#x2013;975. doi: 10.1016/j.leukres.2015.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.leukres.2015.06.003</ArticleId><ArticleId IdType="pubmed">26169445</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulthei&#xdf; C., Willscher E., Paschold L., Gottschick C., Klee B., Bosurgi L., Dutzmann J., Sedding D., Frese T., Girndt M., et al. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. J.&#xa0;Med. Virol. 2023;95 doi: 10.1002/jmv.28364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28364</ArticleId><ArticleId IdType="pmc">PMC9878213</ArticleId><ArticleId IdType="pubmed">36458566</ArticleId></ArticleIdList></Reference><Reference><Citation>Lempp F.A., Soriaga L.B., Montiel-Ruiz M., Benigni F., Noack J., Park Y.J., Bianchi S., Walls A.C., Bowen J.E., Zhou J., et al. Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies. Nature. 2021;598:342&#x2013;347. doi: 10.1038/s41586-021-03925-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03925-1</ArticleId><ArticleId IdType="pubmed">34464958</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson J.D., Ray A., Marcon C., Dos Santos Natividade R., Dorrazehi G.M., Durlet K., Koehler M., Alsteens D. Single-Molecule Analysis of SARS-CoV-2 Binding to C-Type Lectin Receptors. Nano Lett. 2023;23:1496&#x2013;1504. doi: 10.1021/acs.nanolett.2c04931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.nanolett.2c04931</ArticleId><ArticleId IdType="pmc">PMC9924085</ArticleId><ArticleId IdType="pubmed">36758952</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado T.L., Santos A.C., Azamor T., da Silva A.M.V., Pimenta V.R., Tubar&#xe3;o L.N., da Silva A.D.S., Flores Rodrigues D.D.R., M&#xfc;ller R., Pinto M.A., et al. CLEC5A expression can be triggered by spike glycoprotein and may be a potential target for COVID-19 therapy. J.&#xa0;Med. Virol. 2023;95 doi: 10.1002/jmv.28427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28427</ArticleId><ArticleId IdType="pmc">PMC9880667</ArticleId><ArticleId IdType="pubmed">36571274</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao C., Zeng J., Jia N., Stavenhagen K., Matsumoto Y., Zhang H., Li J., Hume A.J., M&#xfc;hlberger E., van Die I., et al. SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors. bioRxiv. 2020 doi: 10.1101/2020.07.29.227462. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.07.29.227462</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantzel R.H., Kj&#xe6;r M.B., Laursen T.L., Kazankov K., George J., M&#xf8;ller H.J., Gr&#xf8;nb&#xe6;k H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front. Med. 2020;7 doi: 10.3389/fmed.2020.615599.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.615599</ArticleId><ArticleId IdType="pmc">PMC7820116</ArticleId><ArticleId IdType="pubmed">33490096</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M., Cohn D.M. The Role of Complement in Hereditary Angioedema. Transfus. Med. Rev. 2019;33:243&#x2013;247. doi: 10.1016/j.tmrv.2019.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2019.08.002</ArticleId><ArticleId IdType="pubmed">31676220</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen E.W., Johansen H.T., Gaudesen O., Osterud B., Olsen J.O., H&#xf8;g&#xe5;sen K., Hack C.E., Mollnes T.E. C3 is activated in hereditary angioedema, and C1/C1-inhibitor complexes rise during physical stress in untreated patients. Scand. J. Immunol. 1995;42:679&#x2013;685. doi: 10.1111/j.1365-3083.1995.tb03711.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3083.1995.tb03711.x</ArticleId><ArticleId IdType="pubmed">8552992</ArticleId></ArticleIdList></Reference><Reference><Citation>Kajdacsi E., Jandrasics Z., Veszeli N., Mako V., Koncz A., Gulyas D., Kohalmi K.V., Temesszentandrasi G., Cervenak L., Gal P., et al. Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients. Front. Immunol. 2020;11:794. doi: 10.3389/fimmu.2020.00794.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00794</ArticleId><ArticleId IdType="pmc">PMC7214733</ArticleId><ArticleId IdType="pubmed">32431708</ArticleId></ArticleIdList></Reference><Reference><Citation>Waldo F.B., West C.D. Quantitation of (C1INH)2 C1r-C1s complexes in glomerulonephritis as an indicator of C1 activation. Clin. Immunol. Immunopathol. 1987;42:239&#x2013;249. doi: 10.1016/0090-1229(87)90011-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0090-1229(87)90011-0</ArticleId><ArticleId IdType="pubmed">3026704</ArticleId></ArticleIdList></Reference><Reference><Citation>Auda G., Holme E.R., Davidson J.E., Zoma A., Veitch J., Whaley K. Measurement of complement activation products in patients with chronic rheumatic diseases. Rheumatol. Int. 1990;10:185&#x2013;189. doi: 10.1007/BF02274831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02274831</ArticleId><ArticleId IdType="pubmed">2075370</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Schank M., Wang L., Dang X., Cao D., Khanal S., Nguyen L.N.T., Zhang Y., Wu X.Y., Adkins J.L., et al. Plasma biomarkers for systemic inflammation in COVID-19 survivors. Proteomics. Clin. Appl. 2022;16 doi: 10.1002/prca.202200031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/prca.202200031</ArticleId><ArticleId IdType="pmc">PMC9539278</ArticleId><ArticleId IdType="pubmed">35929818</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso M.J., Lu S., Tang A.F., Durstenfeld M.S., Ho H.E., Goldberg S.A., Forman C.A., Munter S.E., Hoh R., Tai V., et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J.&#xa0;Infect. Dis. 2021;224:1839&#x2013;1848. doi: 10.1093/infdis/jiab490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab490</ArticleId><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan-Blitz L.T., Akbari O., Kojima N., Saavedra E., Chellamuthu P., Denny N., MacMullan M.A., Hess V., Shacreaw M., Brobeck M., et al. Unique immune and inflammatory cytokine profiles may define long COVID syndrome. Clin. Exp. Med. 2023;23:2925&#x2013;2930. doi: 10.1007/s10238-023-01065-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10238-023-01065-6</ArticleId><ArticleId IdType="pmc">PMC10105906</ArticleId><ArticleId IdType="pubmed">37061998</ArticleId></ArticleIdList></Reference><Reference><Citation>Zang C., Zhang Y., Xu J., Bian J., Morozyuk D., Schenck E.J., Khullar D., Nordvig A.S., Shenkman E.A., Rothman R.L., et al. Data-driven analysis to understand long COVID using electronic health records from the RECOVER initiative. Nat. Commun. 2023;14:1948. doi: 10.1038/s41467-023-37653-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-37653-z</ArticleId><ArticleId IdType="pmc">PMC10080528</ArticleId><ArticleId IdType="pubmed">37029117</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner-Stokes L., Corner E.J., Siegert R.J., Brown C., Wallace S., Highfield J., Bear D., Aitken L.M., Montgomery H., Puthucheary Z. The post-ICU presentation screen (PICUPS) and rehabilitation prescription (RP) for intensive care survivors part I: Development and preliminary clinimetric evaluation. J.&#xa0;Intensive Care Soc. 2022;23:253&#x2013;263. doi: 10.1177/1751143720988715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1751143720988715</ArticleId><ArticleId IdType="pmc">PMC9411778</ArticleId><ArticleId IdType="pubmed">36033253</ArticleId></ArticleIdList></Reference><Reference><Citation>Youden W.J. Index for rating diagnostic tests. Cancer. 1950;3:32&#x2013;35. doi: 10.1002/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0142(1950)3:1&lt;32::aid-cncr2820030106&gt;3.0.co;2-3</ArticleId><ArticleId IdType="pubmed">15405679</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>